Abnormal CCND1 expression is found in the majority of mantle ter (MTC), also called the BCL1 locus is involved in approxicell lymphomas (MCL) and in a minority of other mature B cell mately 40% of t(11;14) positive MCL, whereas breakpoints malignancies. Its evaluation can therefore aid diagnostic classiwithin mTC1 (approximately 20 kb telomeric to the MTC) and fication, in conjunction with clinical, morphological, immunomTC2 (immediately centromeric/5′ to CCND1) occur less frephenotypic and cytogenetic analysis. We describe a rapid slotquently. 6 Regardless of the precise breakpoint, the translo- 
Introduction consequence is aberrant CCND1 expression, the presence or absence of RNA or protein expression is likely to provide the The classification of mature B lymphoproliferative disorders greatest diagnostic aid. Although CCND1 antibodies exist, 15 is still largely based on clinical, histological, cytological and their specificity and sensitivity have not been widely tested, immunological criteria. Recent developments in cytogenetics and in any case their accurate evaluation should be performed and molecular genetics have provided additional diagnostic in parallel with other techniques assessing CCND1. Northern criteria, whose relative roles with respect to the above are curblot analysis currently represents the 'gold standard' for rently under evaluation. mRNA expression, demonstrating 4.5 and 1.7 kb transcripts. 16 The diagnosis of mantle cell lymphoma (MCL) can be diffiThis technique is, however, dependent on the availability of cult, particularly if appropriately conserved material is not relatively large quantities of high quality RNA and is not ideavailable for full immunophenotypic analysis. Its poor progally adapted to routine molecular diagnostic laboratories. We nosis makes accurate identification important for evaluation have therefore developed a simple, rapid slot-blot CCND1 of therapeutic protocols. Detection of the molecular genetic screening technique which requires relatively little RNA but hallmark of this subtype of lymphoma should therefore aid is semi-quantitative, sensitive and reproducible. diagnosis. The t(11;14)(q13;q32) is found predominantly, but not exclusively, in MCL, when it has been identified in approximately 70% of histologically defined cases. 1 It has also Materials and methods been described in multiple myeloma (MM), splenic lymphoma with villous lymphocytes (SLVL), B prolymphocytic leukemia Patient and control material (B-PLL) and in rare cases of apparently typical chronic lymphocytic leukemia. 2, 3 The majority of molecular analyses have CCND1 expression was assessed on cryopreserved diagnostic been performed in t(11;14) positive MCL. The breakpoints on material obtained, with informed consent, from patients inveschromosome 14 cluster within the immunoglobulin heavy tigated for, or to exclude, lymphoproliferative disorders. chain locus at band 14q32, usually occurring at the JH segLymph nodes were snap frozen by plunging into liquid nitroments, whereas the chromosome 11q13 breakpoints are much gen, followed by conservation at −80°C until disruption more heterogeneous, extending from the CCND1/cyclinD1 immediately prior to RNA extraction. Peripheral blood lymgene to at least 150 kb upstream (centromeric). 1, 4, 5 Preferential phocyte (PBL) and bone marrow aspirates were separated by breakpoints have been identified: the major translocation clusdensity gradient centrifugation prior to immediate RNA extraction or initial cryopreservation in dimethyl sulphoxide. served material was available for appropriate immunophenoMembranes were rinsed twice with 2 × SSC, washed for typic analysis, particularly detection of CD23 expression 30 min with a 2 × SSC, 0.5% SDS solution at 55°C, and (group 1A), and nine patients for whom only fixed material exposed for up to 16 h, and usually for 3-6 h, at −80°C with was available at initial diagnosis and in whom it was therefore intensifying screens. Assessment of DNA contamination of necessary to base the tentative diagnosis on histological RNA slot blots was undertaken by re-hybridization with a mixappearances and partial immunophenotype (group 1B). The ture of two chromosome 11q23, MLL intronic probes, 15 control group (n = 22) included seven chronic lymphocytic and 19.
leukemias, five diffuse small cell lymphomas, classified as Autoradiograms were digitally scanned and densities anasmall lymphocytic lymphoma (SLL) in the REAL classilyzed with Scananalysis software (Specom Research, Fergufication, 18 four folicular lymphomas, one polyclonal B cell son, MO, USA). After subtraction of background density proliferation, three reactive lymph nodes, one normal PBL, (calculated as the average of three distinct background and one normal bone marrow. These included a total of nine regions), the final CCND1 expression was obtained by initial lymph node biopsies, 12 peripheral blood samples and one independent normalization of the three concentrations of bone marrow aspirate. Karyotype analysis had been perfor-CCND1/actin density ratios with that obtained for the REC-1 med in all the SLL and 4 CLL, with no t(11;14) being detected. reference cell line. CCND1 sample expression was expressed as a ratio of the REC-1 cell line CCND1 expression. PBL or HL-60 RNA was analyzed as a negative control on each mem-CCND1 expression by slot-blot analysis and brane, in order to assess variability in baseline positivity comparison with immunophenotype between analyses. CCND1 expression was calculated using the following formula:
All 55 samples analyzed demonstrated a positive ␤-actin signal, although this varied in intensity (Figure 1a ). The mean ͫ (CCND1/actin) 0.5 g RNA sample (CCND1/actin) 0.5 g REC1 RNA level of CCND1 expression in the control group, calculated as described above, was 0.02 ± 0.04 (range 0-0.09; n = 22).
The threshold for CCND1 positivity of a sample was therefore taken to be greater than 3 standard deviations from the mean + (CCND1/actin) 2 g RNA sample (CCND1/actin) 2 g REC1 RNA ͬͲ 3 (0.14). A PBL (nine experiments) or HL60 (five experiments) RNA-negative control sample was included on each membrane. Mean values for PBL were 0.028 (0-0.09), and for Attention was paid to the level of exposure necessary for reproducible quantitation. Background noise was measured as HL60 (six slots) 0.05 (0-0.11) CCND1 expression in the HL60 cell line was found to be slightly superior to PBL values, posthe mean of three random fields at a distance from slot-blot samples for each membrane. ␤-Actin autoradiogram exposure sibly indicating low level expression, as recently reported, 19 but remained below the cut-off limit selected here on all did not exceed 6 h since longer exposure times led to overassessment of the quality of the RNA in partially degraded five analyses. Figure 1b , and the distribution of CCND1 values CD5 − CD23 + and FMC7 − . Indeed, after morphological in the MCL and control groups in Figure 2 . CCND1 levels revision in the light of immunophenotypic and CCND1 data, tended to be higher in peripheral blood than lymph node five were re-classified as SLL and one as a probable marginal samples (Figure 2 ), presumably reflecting a higher proportion zone lymphoma. It is therefore clear that accurate diagnosis of malignant cells in the former. The levels seen in the 11 of MCL on fixed material in the absence of adequate immunopositive peripheral blood samples were in keeping with this, phenotypic, CCND1 and/or karyotypic data can be difficult. in so far as the two patients with the lowest CCND1 levels (UPN 616 and 897) were those with the lowest lymphocyte counts, in which residual normal cells represent a greater portion of the RNA analyzed.
MCL classically express CD5 but not CD23, and frequently Classical karyotype analysis allowed detection of a A very different picture was, however, observed in the nine t(11;14)(q13;q32) in 11/17 (65%) CCND1-positive MCL group suspected MCL (group 1B) for which the preliminary diagnosis 1A cases tested, including 7/9 (78%) PB or BM samples and had been made on fixed material, prior to availability of full 3/7 (43%) lymph node samples. Of the three CCND1-negative immunophenotypic data. None of this category was found to group 1B cases analyzed, none was t(11;14) positive and one be CCND1 positive (Table 1 ). All cases with lymph node demonstrated a trisomy 12, characteristic of CLL/SLL. involvement were initially classified as small cell lymphoma 
Figure 2
Normalized CCND1 expression distribution of mantle cell lymphomas and control group. Squares represent peripheral blood lymphocytes or bone marrow samples, diamonds represent lymph nodes or tumor samples.
Comparison with Northern blot analysis in excess of approximately 10% of REC-1. The 6% and the 3% dilution was not distinguishable from the control group. The detection of low level CCND1 expression was slightly In order to determine whether the values obtained were specific, Northern blot analysis was performed for five slot-blot better with lower quantities of RNA (Figure 3) , presumably due to a decreased risk of saturation of the autoradiogram. CCND1-positive samples with sufficient RNA (Figure 1c) . Three samples showed predominant 1.7 kb transcripts, one predominant 4.5 kb transcripts and one demonstrated approximate equal intensity bands. RNA samples were free of Discussion contaminating high molecular weight DNA by Northern blot analysis. This was confirmed by hybridizing two representa-
In this study we demonstrate that slot-blot detection of CCND1 expression is a simple, rapid, reliable technique that tive slot-blot membranes with chromosome 11q23, MLL intronic probes, capable of detecting DNA but not RNA. No is well adapted to routine molecular diagnostic laboratories. It is sensitive enough to separate CCND1 expressing from nonsignal was observed after 24 h exposure and only a very faint signal was observed after 6 days exposure (data not shown).
expressing tumour cells easily, since no doubtful cases were observed in the 25 true MCL, the nine potential MCL and the It is therefore unlikely that the RNA samples were contaminated by significant quantities of DNA.
22 control cases analyzed. The CCND1 levels observed in the control group were Autoradiogram density quantification of both transcripts showed that the Northern blot CCND1/actin ratios were comalways weak, corresponding to background noise or to the rare CCND1 expressing cells that can be found in reactive parable to the slot-blot values (Figure 1c) . Thus, although the relative intensity of the two transcripts is obviously not lymph nodes. 18 HL60 cell line expression was found to be superior to PBL, while always lower than CCND1-positive assessed by slot-blot, the quantitative information provided is similar.
patients. As this cell line was reported to express low level CCND1 by Northern blot and competitive RT-PCR, 19 alternative, negative cell lines would be preferable as negative controls. 19 Based on this observation, we cannot exclude that the Sensitivity testing technique proposed here does not underestimate low level expression of CCND1. In order to assess the sensitivity and the reproducibility of the system, different concentrations of REC-1 RNA were diluted Contrary to Northern or Western blot analysis, relatively little material is required for slot-blot analysis. We have used into PBL RNA. Each dilution was studied with 0.5, 1 and 2 g RNA, and each point was done in duplicate. CCND1/actin three independent concentrations of RNA (total 3.5 g), but have recently adapted this to duplicate 1 g (0.5 g if the ratios were quantified independently for each point and are shown in Figure 3 , as are the mean values obtained for each quantity of material is limiting) sample analysis, with no loss of discrimination (data not shown). This reduces sample prepdilution point. CCND1 expression could be detected at values aration time considerably. Analysis can be successfully positive and negative cases was highly critical. 10 Given the non-linear nature of PCR amplification and the plateau effect, applied to OCT-embedded biopsies remaining after pathological examination. Despite the small amounts of RNA used, the we believe that this technique is not well adapted to CCND1 detection. A recently described comparative RT-PCR amplifiresults of slot-blot analysis were very close to those observed for Northern blotting, demonstrating its specificity and sensication of CCND1, D2 and D3 transcripts, using a common 5′ consensus primer 19 may, however, minimize some of these tivity, without the drawbacks. It should, however, be emphasized that reproducible quantification is dependent on minimal limitations while being better adapted to 'case by case' analysis than slot-blot hybridization. We are currently evaluating background non-specific hybridization and avoidance of excessive, saturating, exposure times. The quantification the relative interest of comparative CCND1-3 RT-PCR and slot blot analysis. method described here can be improved by the integration of the radioactivity emission by a phospho-imager, thus allowing
One possible drawback of all RNA-based techniques is their dependence on high quality cryopreserved material. In our improved linear measurement of signals. After RNA extraction, the whole technique can be realized in 48 to 72 h, experience, the delay occurring between lymph node biopsy and freezing is determinant. It is possible that analysis of proincluding the hybridization of the two probes. While we have not exploited this possibility, the use of non-radioactive probe tein extracts by Western blotting may be less fragile in this respect and several CCND1 antibodies have been shown to labelling techniques should be perfectly feasible. In common with all membrane-based techniques, slot-blot analysis is best work well by this technique. The use of CCND1-specific antibodies for immunohistochemical analysis has several inherent adapted to batched analysis, which can pose potential problems if sample throughput is low. This argues for a certain advantages compared to slot-blot analysis, including rapidity, economy, ease of 'case by case' analysis and identification of degree of centralization of diagnostic material and obviously limits the interest of this technique for a rapid aid to diagnosis. the cellular origin of the CCND1 protein. Although several such antibodies are available, 10,15,20 it appears that their conIn samples with partially degraded RNA, the ␤-actin values become indistinguishable from background noise readings ditions of use require particular attention. Slot-blot analysis will, therefore, provide an alternative technique while these and the CCND1:␤-actin ratio values becomes unreliable. We therefore recommend that any sample with a ␤-actin value techniques are optimized, and will provide a basis for comparative analysis. This technique will also allow sequential less than 20% greater than the background value be considered uninterpretable.
rehybridization of additional potential oncogenic transcripts.
Since there is increasing evidence that the prognosis of Slot-blot analysis will obviously not allow determination of the size of CCND1 transcripts. To our knowledge, there is no CCND1 expressing MCL is dependent on other parameters, including p53 21-23 mutation or loss of p16/p21 expression, 24, 25 evidence suggesting that the relative intensities of the 4.5 and 1.5 kb transcripts correlates with oncogenic potential. Initial comparison of the level of expression of these transcripts on the same RNA sample may help prognostic evaluation. slot-blot screening could, however, be complemented by Northern analysis of positive cases, in order to address this Sensitivity testing showed a limit of approximately 10% of CCND1 expressing cells, similar to that obtained by comparaissue.
Alternative possible techniques for the detection of CCND1 tive RT-PCR analysis. 19 Partial infiltration of the sample can therefore be detected by this technique, but it will not provide expression include reverse transcriptase (RT)-PCR amplification from RNA and immunohistological/cytochemical reliable results in the presence of 'a few abnormal cells', nor will it be useful for the detection of minimal residual disease. analysis. Non-competitive RT-PCR has been successfully used in MCL, but the number of cycles allowing discrimination of Despite these limitations, our quantitative results suggest that exist, as described here for patient UPN 608, and that
